Concepts (251)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 8 | 2025 | 972 | 2.220 |
Why?
|
| Mortality | 5 | 2019 | 174 | 2.000 |
Why?
|
| Cardiovascular Diseases | 5 | 2022 | 729 | 1.610 |
Why?
|
| Health Status | 4 | 2020 | 432 | 1.430 |
Why?
|
| Social Support | 5 | 2016 | 438 | 1.370 |
Why?
|
| Social Class | 5 | 2017 | 286 | 1.210 |
Why?
|
| Brain | 5 | 2025 | 1452 | 1.170 |
Why?
|
| Staphylococcal Infections | 3 | 2023 | 65 | 1.080 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2023 | 62 | 0.940 |
Why?
|
| Prescription Drugs | 1 | 2025 | 32 | 0.920 |
Why?
|
| Carrier State | 3 | 2023 | 33 | 0.920 |
Why?
|
| Stroke | 2 | 2023 | 348 | 0.860 |
Why?
|
| Staphylococcus aureus | 3 | 2023 | 91 | 0.860 |
Why?
|
| Common Cold | 1 | 2023 | 5 | 0.810 |
Why?
|
| Glutamic Acid | 1 | 2023 | 131 | 0.780 |
Why?
|
| Health Status Indicators | 3 | 2008 | 90 | 0.750 |
Why?
|
| Microglia | 2 | 2023 | 204 | 0.750 |
Why?
|
| Interpersonal Relations | 2 | 2014 | 216 | 0.730 |
Why?
|
| Middle Aged | 22 | 2025 | 11819 | 0.730 |
Why?
|
| Humans | 40 | 2025 | 42163 | 0.720 |
Why?
|
| Caregivers | 1 | 2024 | 195 | 0.710 |
Why?
|
| Health Services Accessibility | 2 | 2024 | 680 | 0.700 |
Why?
|
| Male | 28 | 2025 | 22779 | 0.680 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2020 | 19 | 0.670 |
Why?
|
| Rural Population | 2 | 2023 | 352 | 0.660 |
Why?
|
| Educational Status | 2 | 2020 | 335 | 0.650 |
Why?
|
| Female | 28 | 2025 | 24018 | 0.650 |
Why?
|
| Adult | 22 | 2024 | 13458 | 0.620 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 471 | 0.620 |
Why?
|
| Forecasting | 1 | 2020 | 136 | 0.610 |
Why?
|
| Astrocytes | 2 | 2020 | 244 | 0.610 |
Why?
|
| Depressive Disorder, Major | 2 | 2014 | 128 | 0.590 |
Why?
|
| Cross-Sectional Studies | 10 | 2023 | 3077 | 0.590 |
Why?
|
| Blood Glucose | 1 | 2020 | 386 | 0.570 |
Why?
|
| Aged | 15 | 2025 | 7982 | 0.530 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2016 | 10 | 0.520 |
Why?
|
| Presenilin-1 | 1 | 2016 | 27 | 0.510 |
Why?
|
| Nutrition Surveys | 5 | 2022 | 263 | 0.490 |
Why?
|
| United States | 12 | 2024 | 5072 | 0.490 |
Why?
|
| Risk Factors | 8 | 2025 | 3942 | 0.490 |
Why?
|
| Spouses | 1 | 2016 | 38 | 0.480 |
Why?
|
| Social Behavior | 1 | 2017 | 160 | 0.470 |
Why?
|
| Central Nervous System | 1 | 2016 | 150 | 0.450 |
Why?
|
| Social Environment | 2 | 2011 | 218 | 0.440 |
Why?
|
| Loneliness | 1 | 2014 | 22 | 0.420 |
Why?
|
| Depression | 3 | 2022 | 837 | 0.410 |
Why?
|
| NF-kappa B | 1 | 2016 | 355 | 0.400 |
Why?
|
| Arizona | 3 | 2023 | 118 | 0.360 |
Why?
|
| Mutation | 1 | 2016 | 1169 | 0.360 |
Why?
|
| Mice, Transgenic | 3 | 2020 | 658 | 0.360 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 1066 | 0.340 |
Why?
|
| Serine Endopeptidases | 2 | 2023 | 48 | 0.330 |
Why?
|
| Prospective Studies | 4 | 2020 | 1574 | 0.320 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2023 | 78 | 0.320 |
Why?
|
| Coronary Disease | 2 | 2013 | 123 | 0.310 |
Why?
|
| Neurons | 2 | 2018 | 1246 | 0.310 |
Why?
|
| Risk Assessment | 3 | 2022 | 845 | 0.310 |
Why?
|
| Mexican Americans | 2 | 2008 | 224 | 0.300 |
Why?
|
| Neoplasms | 1 | 2020 | 1341 | 0.300 |
Why?
|
| Personal Satisfaction | 1 | 2008 | 74 | 0.290 |
Why?
|
| Social Identification | 1 | 2008 | 63 | 0.280 |
Why?
|
| Insulin | 2 | 2020 | 255 | 0.270 |
Why?
|
| Adolescent | 9 | 2013 | 5950 | 0.270 |
Why?
|
| Cause of Death | 2 | 2020 | 183 | 0.270 |
Why?
|
| Health Behavior | 2 | 2008 | 568 | 0.260 |
Why?
|
| Amyloid beta-Protein Precursor | 2 | 2018 | 95 | 0.260 |
Why?
|
| Mexico | 2 | 2023 | 286 | 0.250 |
Why?
|
| Smoking | 3 | 2008 | 1019 | 0.250 |
Why?
|
| Overweight | 1 | 2008 | 248 | 0.240 |
Why?
|
| Animals | 8 | 2025 | 16695 | 0.240 |
Why?
|
| Gene Expression | 2 | 2020 | 692 | 0.240 |
Why?
|
| Aged, 80 and over | 4 | 2025 | 2803 | 0.230 |
Why?
|
| Affect | 1 | 2007 | 177 | 0.230 |
Why?
|
| Obesity | 4 | 2020 | 1131 | 0.230 |
Why?
|
| Self Concept | 1 | 2006 | 170 | 0.220 |
Why?
|
| Health Surveys | 3 | 2013 | 401 | 0.220 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2011 | 959 | 0.210 |
Why?
|
| Attitude to Health | 1 | 2007 | 336 | 0.210 |
Why?
|
| Antiporters | 1 | 2023 | 13 | 0.210 |
Why?
|
| Cystine | 1 | 2023 | 14 | 0.210 |
Why?
|
| Cells, Cultured | 3 | 2016 | 1617 | 0.210 |
Why?
|
| Case-Control Studies | 2 | 2025 | 1266 | 0.210 |
Why?
|
| Feasibility Studies | 1 | 2024 | 238 | 0.210 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 512 | 0.200 |
Why?
|
| Military Personnel | 1 | 2024 | 109 | 0.200 |
Why?
|
| Oral Health | 1 | 2024 | 86 | 0.200 |
Why?
|
| Socioeconomic Factors | 2 | 2020 | 1221 | 0.200 |
Why?
|
| Social Desirability | 1 | 2002 | 6 | 0.200 |
Why?
|
| Personality Tests | 1 | 2002 | 7 | 0.200 |
Why?
|
| Child, Preschool | 2 | 2024 | 1516 | 0.190 |
Why?
|
| Patient Participation | 1 | 2023 | 87 | 0.190 |
Why?
|
| Anxiety Disorders | 1 | 2005 | 319 | 0.190 |
Why?
|
| Hypertension | 2 | 2006 | 823 | 0.180 |
Why?
|
| Risk | 2 | 2020 | 289 | 0.180 |
Why?
|
| N-Methylaspartate | 1 | 2022 | 58 | 0.180 |
Why?
|
| Serine | 1 | 2022 | 81 | 0.180 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 2 | 2023 | 16 | 0.180 |
Why?
|
| Patient Selection | 1 | 2023 | 192 | 0.180 |
Why?
|
| Dental Caries | 1 | 2022 | 55 | 0.180 |
Why?
|
| Statistics as Topic | 2 | 2016 | 123 | 0.180 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2022 | 133 | 0.170 |
Why?
|
| Infant, Newborn | 1 | 2024 | 960 | 0.170 |
Why?
|
| Violence | 1 | 2002 | 133 | 0.170 |
Why?
|
| Cohort Studies | 1 | 2025 | 1729 | 0.170 |
Why?
|
| Infant | 1 | 2024 | 1143 | 0.170 |
Why?
|
| Schools | 1 | 2002 | 283 | 0.160 |
Why?
|
| Ubiquitination | 1 | 2019 | 60 | 0.160 |
Why?
|
| Interleukin-1beta | 1 | 2019 | 74 | 0.160 |
Why?
|
| Weight Loss | 2 | 2012 | 138 | 0.150 |
Why?
|
| Sex Distribution | 1 | 2020 | 224 | 0.150 |
Why?
|
| Indians, North American | 1 | 2022 | 179 | 0.150 |
Why?
|
| Age Distribution | 1 | 2020 | 249 | 0.150 |
Why?
|
| Morbidity | 1 | 2019 | 97 | 0.150 |
Why?
|
| Signal Transduction | 3 | 2023 | 2111 | 0.150 |
Why?
|
| Insulysin | 1 | 2018 | 1 | 0.150 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 1051 | 0.150 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2019 | 90 | 0.150 |
Why?
|
| Nerve Tissue Proteins | 2 | 2023 | 382 | 0.150 |
Why?
|
| Survival Rate | 1 | 2020 | 353 | 0.150 |
Why?
|
| Peptide Fragments | 1 | 2020 | 301 | 0.150 |
Why?
|
| Retrospective Studies | 1 | 2025 | 2485 | 0.140 |
Why?
|
| Young Adult | 4 | 2021 | 4936 | 0.140 |
Why?
|
| Defense Mechanisms | 1 | 1997 | 10 | 0.140 |
Why?
|
| tau Proteins | 2 | 2016 | 182 | 0.140 |
Why?
|
| Arousal | 1 | 1997 | 95 | 0.130 |
Why?
|
| Apolipoprotein E4 | 1 | 2017 | 62 | 0.130 |
Why?
|
| Lysosomes | 1 | 2017 | 88 | 0.130 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2016 | 35 | 0.130 |
Why?
|
| Fibrinogen | 1 | 2016 | 24 | 0.130 |
Why?
|
| Mice | 5 | 2023 | 6490 | 0.130 |
Why?
|
| Insulin Resistance | 1 | 2018 | 199 | 0.130 |
Why?
|
| Telomere | 1 | 2017 | 59 | 0.130 |
Why?
|
| Hippocampus | 2 | 2018 | 591 | 0.130 |
Why?
|
| Age Factors | 1 | 2020 | 1139 | 0.130 |
Why?
|
| Uric Acid | 1 | 2016 | 29 | 0.130 |
Why?
|
| Aging | 1 | 2022 | 764 | 0.130 |
Why?
|
| Glycoside Hydrolases | 1 | 2016 | 7 | 0.120 |
Why?
|
| Autophagy | 1 | 2017 | 136 | 0.120 |
Why?
|
| TNF Receptor-Associated Factor 6 | 1 | 2016 | 4 | 0.120 |
Why?
|
| Cholesterol, LDL | 1 | 2016 | 73 | 0.120 |
Why?
|
| TNF Receptor-Associated Factor 2 | 1 | 2016 | 16 | 0.120 |
Why?
|
| Serum Albumin | 1 | 2016 | 58 | 0.120 |
Why?
|
| Sex Factors | 1 | 2020 | 1008 | 0.120 |
Why?
|
| Muscle, Skeletal | 1 | 2018 | 308 | 0.120 |
Why?
|
| Triglycerides | 1 | 2016 | 146 | 0.120 |
Why?
|
| Friends | 1 | 2016 | 25 | 0.120 |
Why?
|
| Transcription Factor RelA | 1 | 2016 | 41 | 0.120 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2015 | 29 | 0.120 |
Why?
|
| I-kappa B Kinase | 1 | 2016 | 50 | 0.120 |
Why?
|
| Liver | 1 | 2018 | 503 | 0.120 |
Why?
|
| Body Mass Index | 3 | 2013 | 916 | 0.120 |
Why?
|
| C-Reactive Protein | 1 | 2016 | 164 | 0.120 |
Why?
|
| Leukocytes | 1 | 2016 | 79 | 0.120 |
Why?
|
| Embryo, Mammalian | 1 | 2016 | 158 | 0.120 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2019 | 1737 | 0.110 |
Why?
|
| Adaptation, Psychological | 1 | 1997 | 410 | 0.110 |
Why?
|
| Switzerland | 1 | 2014 | 2 | 0.110 |
Why?
|
| Health Status Disparities | 1 | 2020 | 705 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 2 | 2016 | 1804 | 0.110 |
Why?
|
| Prognosis | 1 | 2016 | 850 | 0.100 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 436 | 0.100 |
Why?
|
| Retirement | 1 | 2013 | 12 | 0.100 |
Why?
|
| Quality of Life | 2 | 2008 | 599 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 744 | 0.100 |
Why?
|
| Depressive Disorder | 1 | 2014 | 185 | 0.100 |
Why?
|
| Telephone | 1 | 2012 | 35 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 638 | 0.090 |
Why?
|
| Longevity | 1 | 2013 | 171 | 0.090 |
Why?
|
| Population Surveillance | 1 | 2011 | 245 | 0.080 |
Why?
|
| Phosphorylation | 3 | 2018 | 973 | 0.080 |
Why?
|
| Odds Ratio | 1 | 2011 | 587 | 0.080 |
Why?
|
| Individuality | 2 | 2021 | 53 | 0.080 |
Why?
|
| Personal Autonomy | 1 | 2008 | 21 | 0.070 |
Why?
|
| Adiposity | 2 | 2008 | 155 | 0.070 |
Why?
|
| Rats | 1 | 2016 | 3701 | 0.070 |
Why?
|
| Interviews as Topic | 2 | 2006 | 428 | 0.070 |
Why?
|
| Sick Role | 1 | 2007 | 9 | 0.070 |
Why?
|
| Language | 1 | 2008 | 181 | 0.060 |
Why?
|
| Thinking | 1 | 2007 | 36 | 0.060 |
Why?
|
| Patients | 1 | 2006 | 16 | 0.060 |
Why?
|
| Emigrants and Immigrants | 1 | 2008 | 156 | 0.060 |
Why?
|
| Marital Status | 1 | 2006 | 46 | 0.060 |
Why?
|
| Mental Recall | 1 | 2006 | 81 | 0.060 |
Why?
|
| Health Promotion | 1 | 2012 | 691 | 0.060 |
Why?
|
| Causality | 1 | 2005 | 45 | 0.060 |
Why?
|
| Motor Activity | 1 | 2008 | 438 | 0.060 |
Why?
|
| Mood Disorders | 1 | 2006 | 54 | 0.060 |
Why?
|
| Risk-Taking | 1 | 2008 | 456 | 0.060 |
Why?
|
| Models, Molecular | 2 | 2019 | 875 | 0.060 |
Why?
|
| Stress Disorders, Traumatic, Acute | 1 | 2024 | 2 | 0.060 |
Why?
|
| Norway | 1 | 2024 | 10 | 0.060 |
Why?
|
| Anxiety | 2 | 2006 | 847 | 0.060 |
Why?
|
| Cholesterol | 1 | 2006 | 230 | 0.050 |
Why?
|
| Nasal Cavity | 1 | 2023 | 10 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2018 | 1265 | 0.050 |
Why?
|
| Protein Binding | 2 | 2017 | 1076 | 0.050 |
Why?
|
| Luciferases | 1 | 2023 | 70 | 0.050 |
Why?
|
| Receptors, LDL | 1 | 2023 | 40 | 0.050 |
Why?
|
| Peer Group | 1 | 2024 | 173 | 0.050 |
Why?
|
| Waist Circumference | 2 | 2013 | 90 | 0.050 |
Why?
|
| Factor Analysis, Statistical | 1 | 2002 | 157 | 0.050 |
Why?
|
| Mass Media | 1 | 2002 | 38 | 0.050 |
Why?
|
| Mass Screening | 1 | 2006 | 531 | 0.050 |
Why?
|
| Psychometrics | 1 | 2002 | 350 | 0.040 |
Why?
|
| Sleep | 1 | 2021 | 179 | 0.040 |
Why?
|
| Ubiquitin | 1 | 2019 | 80 | 0.040 |
Why?
|
| Cognition | 1 | 2023 | 458 | 0.040 |
Why?
|
| Synaptosomes | 1 | 2018 | 22 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2002 | 1058 | 0.040 |
Why?
|
| Protein Transport | 1 | 2019 | 295 | 0.040 |
Why?
|
| Receptor, Insulin | 1 | 2018 | 26 | 0.040 |
Why?
|
| Enzyme Activation | 1 | 2019 | 462 | 0.040 |
Why?
|
| Glucose Intolerance | 1 | 2018 | 41 | 0.040 |
Why?
|
| Community-Based Participatory Research | 1 | 2022 | 336 | 0.040 |
Why?
|
| Prevalence | 1 | 2023 | 1597 | 0.040 |
Why?
|
| Galvanic Skin Response | 1 | 1997 | 16 | 0.030 |
Why?
|
| Apolipoprotein E3 | 1 | 2017 | 11 | 0.030 |
Why?
|
| Epistasis, Genetic | 1 | 2017 | 18 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2017 | 20 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2017 | 96 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2017 | 54 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2023 | 1554 | 0.030 |
Why?
|
| Intermediate Filament Proteins | 1 | 2016 | 16 | 0.030 |
Why?
|
| Detergents | 1 | 2016 | 25 | 0.030 |
Why?
|
| 14-3-3 Proteins | 1 | 2016 | 22 | 0.030 |
Why?
|
| Heart Rate | 1 | 1997 | 261 | 0.030 |
Why?
|
| Solubility | 1 | 2016 | 134 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 188 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2018 | 1010 | 0.030 |
Why?
|
| Cell Death | 1 | 2016 | 277 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2017 | 404 | 0.030 |
Why?
|
| Disease Progression | 1 | 2017 | 661 | 0.030 |
Why?
|
| Cell Line | 1 | 2018 | 1416 | 0.030 |
Why?
|
| Genotype | 1 | 2017 | 796 | 0.030 |
Why?
|
| Proteomics | 1 | 2016 | 363 | 0.030 |
Why?
|
| Child | 1 | 2002 | 3381 | 0.030 |
Why?
|
| Cytokines | 1 | 2017 | 661 | 0.030 |
Why?
|
| Personality Assessment | 1 | 2013 | 44 | 0.030 |
Why?
|
| Canada | 1 | 2013 | 157 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1112 | 0.020 |
Why?
|
| Students | 1 | 1997 | 617 | 0.020 |
Why?
|
| Energy Intake | 1 | 2012 | 162 | 0.020 |
Why?
|
| Incidence | 1 | 2013 | 1054 | 0.020 |
Why?
|
| Diet, Reducing | 1 | 2008 | 23 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 2598 | 0.020 |
Why?
|
| Anthropometry | 1 | 2008 | 96 | 0.020 |
Why?
|
| Behavior Therapy | 1 | 2008 | 179 | 0.020 |
Why?
|
| Utah | 1 | 2006 | 10 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2008 | 234 | 0.020 |
Why?
|
| Decision Making | 1 | 2008 | 242 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2008 | 1586 | 0.010 |
Why?
|